NCI, NCRI and EORTC outline risk-assessment approach for biomarker-driven cancer clinical trials

April 29, 2014 by John Bean, Phd
NCI, NCRI and EORTC outline risk-assessment approach for biomarker-driven cancer clinical trials

In an article published in The Lancet Oncology, an NCI (US National Cancer Institute), NCRI (UK National Cancer Research Institute), and EORTC (European Organisation for Research and Treatment of Cancer) working group outline a practical risk-management approach for effective integration of biomarkers into cancer clinical trials. Their work provides the international community with a set of common principles by which biomarkers can be integrated into clinical trials, exchange of data can be facilitated, quality promoted, and research accelerated while simultaneously respecting local approaches and legislation.

Their risk-assessment approach for designing and conducting include risks to patient safety, operational risks, and biomarker development risks, and for each risk they evaluate possible consequences, provide solutions along with examples of these as well as references to helpful resources. Concerning protocol design, the working group recommends items that a protocol should include as well as items that should be assessed during protocol development. For the conduct of the trial, they make recommendations for the close monitoring of variability in test results, and they also make recommendations for particular aspects following completion of the trial.

Dr. Jacqueline Hall, who coordinated this NCI, NCRI, and EORTC working group says, "We readily acknowledge that in today's clinical trial landscape, many stakeholders play a role in . These include regulators, public authorities, and patients, amongst others. By opening this discussion to others, we hope to find solutions to the varied challenges facing molecularly driven clinical research."

Explore further: Clinical trials to investigate prostate cancer treatment

Related Stories

Clinical trials to investigate prostate cancer treatment

April 28, 2014
The way prostate cancer is treated could have a radical re-think as two international clinical trials go ahead.

World-first clinical trial launches for advanced bowel cancer

April 2, 2014
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs and new biomarkers ...

Study shows value of HRQOL assessment in small cell lung cancer

January 28, 2014
An EORTC study published in Lancet Oncology found that health-related quality of life (HRQOL) assessment in small-cell lung cancer randomized clinical trials provides relevant added information in studies where the treatment ...

Timeline reforms increase initiation speed of NCI sponsored clinical trials

June 17, 2013
The National Cancer Institute (NCI) and investigators have reduced the deadlines for initiation of trials with the goal of reaching more patients in need of new treatments, according to a study published June 17 in the Journal ...

Biomarkers predict effectiveness of radiation treatments for cancer

March 27, 2014
An international team of researchers, led by Beaumont Health System's Jan Akervall, M.D., Ph.D., looked at biomarkers to determine the effectiveness of radiation treatments for patients with squamous cell cancer of the head ...

Clinical trials show promise for prostate cancer drug

January 30, 2014
A 30 percent reduction in mortality risk is one of the impressive results achieved in a global clinical drug trial for the treatment of prostate cancer. The full trial data are due to be presented today at one of the world´s ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.